Patent classifications
C07D281/02
15-PGDH INHIBITOR
[Problem]
To provide a compound having a 15-PGDH inhibitory effect.
[Solution]
A compound represented by general formula (1) or a pharmacologically acceptable salt thereof.
15-PGDH INHIBITOR
[Problem]
To provide a compound having a 15-PGDH inhibitory effect.
[Solution]
A compound represented by general formula (1) or a pharmacologically acceptable salt thereof.
A NEW CLASS OF MU-OPIOID RECEPTOR AGONISTS
The present invention provides a compound having the structure:
##STR00001## or a pharmaceutically acceptable salt or ester thereof.
A NEW CLASS OF MU-OPIOID RECEPTOR AGONISTS
The present invention provides a compound having the structure:
##STR00001## or a pharmaceutically acceptable salt or ester thereof.
2,3-DIARYL-1,3-THIAZEPAN-4-ONES COMPOUNDS AND METHODS FOR MAKING
A compound with the following general formula (I) and a general method for making this compound are provided, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10, R.sup.11, R.sup.12, R.sup.13, R.sup.14, R.sup.15 and R.sup.16 are each independently selected from the group that includes H, halogen, nitro, cyano, alkyl, aryl, alkoxy, cycloalkyl, heteroalkyl, heterocyclyl, aralkyl, heteroaryl and heteroaralkyl.
##STR00001##
2,3-DIARYL-1,3-THIAZEPAN-4-ONES COMPOUNDS AND METHODS FOR MAKING
A compound with the following general formula (I) and a general method for making this compound are provided, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10, R.sup.11, R.sup.12, R.sup.13, R.sup.14, R.sup.15 and R.sup.16 are each independently selected from the group that includes H, halogen, nitro, cyano, alkyl, aryl, alkoxy, cycloalkyl, heteroalkyl, heterocyclyl, aralkyl, heteroaryl and heteroaralkyl.
##STR00001##
Carboxylic diarythiazepineamines as mixed mu- and delta-opioid receptor agonists
The present invention provides a compound having the structure: ##STR00001##
or a pharmaceutically acceptable salt or ester thereof, and a method of treating a subject afflicted with a pain, a depressive disorder, a mood disorder, an anxiety disorder, borderline personality disorder, opioid addiction, or opioid withdrawal symptoms by administering the compound to the subject.
Carboxylic diarythiazepineamines as mixed mu- and delta-opioid receptor agonists
The present invention provides a compound having the structure: ##STR00001##
or a pharmaceutically acceptable salt or ester thereof, and a method of treating a subject afflicted with a pain, a depressive disorder, a mood disorder, an anxiety disorder, borderline personality disorder, opioid addiction, or opioid withdrawal symptoms by administering the compound to the subject.
Benzothiazepine compounds and their use as bile acid modulators
The invention relates to 1,5-benzothiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.
CARBOXYLIC DIARYLTHIAZEPINEAMINES AND USES THEREOF
The present disclosure provides a compound having the structure: Formula (I) wherein R.sub.1 is —H or -(alkyl); R.sub.2 is -(alkyl)-CO2H or -(alkyl)-CO2-(alkyl); R.sub.3 is —H or -(alkyl); and X is —Br or —I, or a pharmaceutically acceptable salt or ester thereof, for treating or preventing a neurological disorder, including Huntington’s disease, Rett syndrome, and CDKL5 disorder.